Outcomes and predictors of failure of trocar-guided vaginal mesh surgery for pelvic organ prolapse




Objective


The objective of the study was to compare the 1 year conventional and composite outcomes of trocar-guided vaginal mesh surgery and the identification of the predictors of failure.


Study Design


This was a prospective observational cohort study. Failure outcome definitions were as follows: I, prolapse stage II or greater in mesh treated compartments; II, overall prolapse stage II or greater; III, composite outcome of overall prolapse greater than the hymen and the presence of bulge symptoms or repeat surgery. We used logistic regression to identify predictors of failure.


Results


The results of the study were 1 year follow-up of 433 patients. Treated compartment failure (I) was 15% (95% confidence interval [CI], 12–19). Overall prolapse failure (II) was 41% (95% CI, 36–45). Composite failure (III) was 9% (95% CI, 7–13). Predictor of failure in all outcomes was the combined anterior/posterior mesh with the uterus in situ.


Conclusion


Outcome of prolapse surgery depends on outcome definition. The mesh treated compartment failure outcome (I) and the composite failure outcome (III) appeared not to be statistically different. Consistent factor for failure in all outcomes was the combined anterior/posterior mesh insertion with the uterus in situ.


Pelvic organ prolapse (POP) may occur in up to 50% of parous women. The lifetime risk of undergoing surgery for POP in the general female population to the age of 85 years has recently been reported to be as high as 19-20%. This high likelihood of undergoing surgery for POP combined with the knowledge of anatomic failure rates for native tissue repairs that range between 30% and 70% for the anterior vaginal wall and around 20% for the posterior vaginal wall has led to the increased use of prosthetic mesh in vaginal prolapse surgery with the main aim to reduce anatomic failure rates and increase the durability of repairs.


Most studies have used strict anatomic outcome criteria as proposed by the National Institutes of Health (NIH) Workshop on Standardization of Terminology for Researchers in Pelvic Floor Disorders in 2001 and used patient reported outcomes only as a secondary outcome measure. But recently Barber et al have demonstrated that the postoperative absence of vaginal bulge symptoms had a significant relationship with a patient’s assessment of overall improvement, whereas anatomic success alone did not. The authors therefore suggested that any future definition of success of POP surgery should include the absence of bulge symptoms in addition to anatomic criteria and the absence of retreatment. The authors agreed with Swift et al that the hymen should thereby be regarded as the threshold for anatomic success.


The primary objective of this study was to compare 1-year outcomes of a large cohort of patients who underwent trocar-guided, tension-free vaginal mesh surgery (Prolift; Ethicon, Somerville, NJ) according to the conventional NIH Workshop criteria with the newly suggested composite outcome of Barber et al. The second objective was to identify possible predictors of failure for these outcomes.


Materials and Methods


This prospective observational cohort study is part of an ongoing outcome quality registration project of Radboud University Medical Centre (Nijmegen, The Netherlands), which has been approved by Arnhem-Nijmegen Human Research Committee (April 2006). The present analysis included the 12 month follow-up data of consecutively performed trocar-guided, tension-free vaginal mesh procedures (Prolift; Ethicon) between September 2005 and April 2010. Details of 150 patients in this cohort have previously been reported in a study focusing on de novo prolapse in untreated vaginal compartments, and 93 were part of a randomized controlled trial, comparing mesh with native tissue repair in recurrent prolapse.


Inclusion criteria were increased risk of recurrence, which was considered recurrent pelvic organ prolapse stage II or higher or primary pelvic organ prolapse stage III or higher. Exclusion criteria were (contemplating) pregnancy or a compromised immune system.


Surgery was performed by17 gynecologists in 13 collaborating centers. The range of procedures varied from 1 to 209 (mean 25; median 3). Four performed more than 25 procedures. All gynecologists were trained for the tension-free vaginal mesh procedure as described by Fatton et al. Depending on the prolapsed compartment, mesh insertion could be anterior, posterior, anterior and posterior (in case of uterus or cervix in situ), or total (in case of a prolapsed vaginal vault).


Concomitant native tissue repairs were allowed for other less prolapsed compartments or compartments that were not at increased risk of recurrence. To reduce the risk of mesh exposure, simultaneous hysterectomy or T-incisions were avoided. For most of the participating centers, it was policy not to simultaneously insert a mid urethral sling because of anticipated increased risk on postoperative urinary retention. Patients were counseled on this strategy and the possibility of a second procedure. In case the presence of stress urinary incontinence after surgery necessitated the insertion of a midurethral sling, this was not considered a reintervention for POP and thus not registered as failure; on the other hand, the symptomatic recurrence of POP that necessitated resurgery was a reintervention for POP and thus counted as a failure.


All procedures were performed under perioperative antibiotic prophylaxis. Patients received an indwelling catheter for 1-2 days and a vaginal gauze pack for 24 hours.


Postoperative urinary retention was defined as repeated postvoid residual volume greater than 100 mL measured with a bladder scanner. De novo stress urinary incontinence was considered significant if a patient responded yes or moderately to quite a bit to the following question: do you experience urinary leakage during physical activity, coughing, or sneezing?


The mesh used in the original trocar-guided mesh procedure is monofilament polypropylene mesh, weighing 45 g/m 2 . In 2009, some centers started using a partially absorbable mesh, consisting of a 50-50 blend of monofilament, nonabsorbable polypropylene and absorbable polyglecaprone 25 (Prolift+M; Ethicon). The technique is identical, but the mesh weighs 57 g/m 2 before absorption and after full absorption after 90-120 days, only 31 g/m 2 .


Baseline evaluation included medical history and assessment of POP by using the Pelvic organ Prolapse Quantification (POP-Q) system. Data on symptoms and bother were obtained by the standard Dutch urogynecological questionnaire, which among others contains the Dutch validated version of the Urogenital Distress Inventory (UDI).


Follow-up visits were scheduled at 6 weeks and 6 and 12 months. At 12 months a POP-Q examination was performed and patients were again requested to complete the standard urogynecological questionnaire.


Failure outcomes were defined as follows: (1) outcome I was an NIH failure of mesh-treated compartment, POP stage of II or greater of mesh-treated vaginal compartment(s) or resurgery for POP in mesh-treated compartments within 12 months; (2) outcome II was an NIH failure of overall POP or leading edge of prolapse in any compartment stage of II or greater or resurgery for POP in any compartment within 12 months; or (3) outcome III was an composite outcome failure or a leading edge of any compartment greater than hymen and the presence of bulge symptoms or resurgery for POP within 12 months.


The presence of bulge symptoms was defined as clinically significant if a patient responded yes or moderately to quite a bit to either of the 2 following questions: do you see or do you feel a vaginal bulge?


To determine the minimum sample size, we anticipated on a 90% success rate for the mesh-treated compartments. We considered treatment successful if the 1 sided 95% confidence interval (CI) did not fall below 85%. This resulted in a minimum number of 282 patients that were necessary for inclusion in this study.


Results are summarized as numbers with corresponding percentages or as medians with range. Primary outcomes were failure percentages with 95% CIs per predefined outcome definition. Univariable logistic regression was used to identify possible risk factors of failure in each of the outcomes. Considered risk factors were the patient’s age, menopause, previous POP repair(s), parity, preoperative POP stage, body mass index, location of mesh insertion, the use of the new partially absorbable mesh, mesh combined with native tissue repairs, mesh combined with sacrospinous fixation, the presence of the uterus, operating time, blood loss, complications, and mesh exposure.


Crude odds ratios (ORs) for the possible risk factors of failure for each outcome were calculated with corresponding 90% CIs. To optimize the validity of the logistic model, restriction of the number of test variables was necessary. To ensure that the number of events per variable (EPV) did not drop below 10, only the allowed number of the most significant variables was selected for entry in the multivariable model. Multivariable logistic regression with forward selection was used to identify those variables that were independently related to failure in each of the outcomes. Variables reaching statistical significance at the P < .10 level in the univariable analysis were considered valid for entry in the forward selection model. The adjusted OR with 95% CI are presented. A P value of < .05 was considered statistically significant. Statistical analysis was performed using SPSS 18.0 for Windows (SPSS, Inc, Chicago, IL).




Results


Four hundred thirty-three women met the inclusion criteria for trocar-guided mesh surgery and were included. Four hundred nineteen (97%) completed the 12 month follow-up. Baseline characteristics and preoperative POP stage are presented in Table 1 . The median age of the patients was 64 years (range, 16–93). Seventy-two percent of the patients had a recurrent POP and 67% a POP stage of stage III or greater.



TABLE 1

Baseline characteristics


















































Characteristic Total n (%) or median (range)
Age, y 433 64 (16–93)
BMI, kg/m 2 320 25.6 (18.9–41.8)
Menopause 396 348 (88)
Parity (number) 367 2 (0–7)
Previous POP repair 425 307 (72)
POP
Stage 0 429 0 (0)
Stage I 429 0 (0)
Stage II 429 141 (33)
Stage III 429 266 (62)
Stage IV 429 22 (5)

BMI , body mass index; POP , pelvic organ prolapse.

Milani. Outcomes and predictors of failure of vaginal mesh surgery. Am J Obstet Gynecol 2012.


Table 2 shows peri- and postoperative data. Eighteen percent of patients (n = 77) underwent surgery with a partially absorbable mesh. According to the 12 month follow-up questionnaire, 38 of 280 patients (13.6%) were classified as having de novo stress urinary incontinence.



TABLE 2

Peri- and postoperative data




































































































Variable Total n (%) or median (range)
Location tension-free vaginal mesh
Anterior 433 116 (27)
Posterior 433 152 (35)
Anterior and posterior 433 64 (15)
Total 433 100 (23)
Partially absorbable mesh 433 77 (18)
Mesh procedure combined with native tissue POP repair (mesh combined) 432 83 (19)
Sacrospinous ligament fixation 432 26 (6)
Modified Manchester procedure 432 3 (1)
Anterior colporrhaphy 432 17 (4)
Posterior colporrhaphy 432 18 (4)
Perineal repair 432 9 (2)
Enterocele repair 432 10 (2)
Midurethral sling 432 5 (1)
Operating time, min 417 60 (20–150)
Blood loss, mL 412 100 (0–1300)
Complications a
Rectal serosa lesion 423 2 (0)
Bladder injury 423 9 (2)
Urinary retention 423 34 (8)
Blood loss >500 mL 412 2 (1)
Postoperative hematoma 432 22 (5)
Any complication 432 66 (15)
Mesh exposure within 12 months 425 54 (13)

POP, pelvic organ prolapse.

Milani. Outcomes and predictors of failure of vaginal mesh surgery. Am J Obstet Gynecol 2012.

a Multiple diagnoses possible.



Table 3 shows failure rates per location of mesh insertion for all predefined outcomes. NIH failure of the mesh-treated compartments POP stage of II or greater was 15% (95% CI, 12–19). NIH failure of overall POP stage of II or greater was 41% (95% CI, 36–45) and composite failure was 9% (95% CI, 7–13). Resurgery was performed in 18 of 433 patients (4%), of which 16 (89%) were in the untreated vaginal compartments. Highest failure rates were observed for combined anterior/posterior mesh insertions.



TABLE 3

Failure outcomes at 12 months








































































































Outcome Total n Percentage and 95% CI
I. NIH failure of mesh treated compartment POP stage II or greater or resurgery 415 64 15 (12–19) a
Anterior mesh only 112 20 18 (11–26)
Posterior mesh only 146 9 6 (3–11)
Anterior and posterior mesh 62 21 34 (22–47)
Total mesh 94 14 15 (8–24)
II. NIH failure: overall POP stage II or greater or resurgery 419 170 41 (36–45) a
Anterior mesh only 113 60 53 (43–63)
Posterior mesh only 148 66 45 (36–53)
Anterior and posterior mesh 62 30 48 (36–61)
Total mesh 94 14 15 (8–24)
III. Composite failure: overall POP greater than hymen and bulge symptoms or resurgery 380 35 9 (7–13) a
Anterior mesh only 106 11 10 (5–18)
Posterior mesh only 127 13 10 (6–17)
Anterior and posterior mesh 58 9 16 (7–27)
Total mesh 87 2 2 (0–8)
Resurgery 433 18 4 (2–6)
Mesh-treated compartment 18 2 11 (1–35)
Untreated compartment 18 16 89 (65–99)
Vaginal bulge symptoms 370 43 12 (9–15)

CI, confidence interval; NIH, National Institutes of Health; POP, pelvic organ prolapse.

Milani. Outcomes and predictors of failure of vaginal mesh surgery. Am J Obstet Gynecol 2012.

a Overall failure % (95% CI) per predefined treatment outcome.



Table 4 shows crude ORs with 90% CIs per outcome definition for each of the tested variables. Variables that reached statistical significance at the P < .10 level were considered valid for entry in the multivariable logistic regression model. Because outcome I resulted in just 64 failures, we selected only 7 of the 9 most significant variables for entry in the multivariable regression model.



TABLE 4

Crude OR for the risk of failure for all outcomes, using univariable logistic regression analysis








































































































































































































Variable NIH treated compartment (I) NIH overall POP (II) Composite outcome (III)
n OR (90% CI) n OR (90% CI) n OR (90% CI)
Age, y 415 1.01 (0.99–1.03) 419 1.01 (0.99–1.02) 380 0.99 (0.96–1.01)
Menopause, p 378 0.73 (0.31–1.71) 382 0.69 (0.35–1.34) 346 0.43 (0.16–1.14)
Previous POP repair, p 407 0.71 (0.44–1.15) 410 0.92 (0.64–1.33) 371 0.97 (0.51–1.86)
Parity, number 352 1.02 (0.82–1.26) 355 1.01 (0.86–1.18) 326 0.93 (0.70–1.23)
Preoperative POP stage 411 415 376
Stage II 1.00 (reference) 1.00 (reference) 1.00 (reference)
Stage III or greater 2.35 (1.35–4.11) a 1.50 (1.05–2.14) a 1.13 (0.59–2.15)
Body mass index, kg/m 2 408 1.01 (1.00–1.02) a 412 1.01 (0.99–1.02) 376 1.01 (0.99–1.01)
Location mesh b 414 417 378
Total 1.00 (reference) 1.00 (reference) 1.00 (reference)
Anterior 1.24 (0.66–2.32) 6.47 (3.66–11.42) a 4.92 (1.36–17.84) a
Posterior 0.38 (0.18–0.79) a 4.60 (2.66–7.96) a 4.85 (1.36–17.28) a
Anterior plus posterior 2.93 (1.53–5.60) a 5.36 (2.84–10.10) a 7.81 (2.09–29.20) a
Partially absorbable mesh, p 415 3.08 (1.87–5.08) a 418 1.49 (0.98–2.28) 366 1.24 (0.59–2.58)
Mesh combined, p 414 1.06 (0.61–1.85) 417 0.88 (0.58–1.33) 378 1.05 (0.51–2.18)
Mesh combined with SSF, p 410 2.16 (1.00–4.64) a 413 0.63 (0.31–1.29) 363 0.41 (0.07–2.24)
Uterus in situ, p 417 2.17 (1.38–3.42) a 417 2.13 (1.50–3.02) a 366 1.61 (0.89–2.94)
Operating time, per 20 min 400 1.01 (1.00–1.02) a 402 0.99 (0.99–1.00) 364 1.00 (0.99–1.01)
Blood loss, per 100 mL 396 1.00 (0.99–1.00) 398 0.99 (0.99–1.00) a 360 0.99 (0.99–1.00)
Any complication, p 414 0.77 (0.33–1.49) 417 0.81 (0.51–1.29) 378 0.30 (0.09–1.01)
Bladder injury, p 405 0.63 (0.11–3.64) 408 3.51 (1.11–11.05) a 370 1.20 (0.21–7.06)
Postoperative hematoma, p 414 0.53 (0.15–1.84) 417 1.01 (0.48–2.09) 378 0.50 (0.09–2.78)
Mesh exposure, p 409 0.85 (0.42–1.74) 413 0.55 (0.32–0.93) a 372 1.14 (0.49–2.64)

CI, confidence interval; NIH, National Institutes of Health; OR, odds ratio; p, absent coded as 0, present coded as 1; POP, pelvic organ prolapse; SSF, sacrospinous fixation.

Milani. Outcomes and predictors of failure of vaginal mesh surgery. Am J Obstet Gynecol 2012.

a Variables reaching statistical significance at the P < .10 level, valid for entry in the selection procedure;


b Total mesh for post hysterectomy vaginal vault prolapse, anterior plus posterior mesh for prolapse of anterior and posterior compartments with the uterus in situ.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

May 15, 2017 | Posted by in GYNECOLOGY | Comments Off on Outcomes and predictors of failure of trocar-guided vaginal mesh surgery for pelvic organ prolapse

Full access? Get Clinical Tree

Get Clinical Tree app for offline access